Forte Biosciences Inc (FBRX)
0.739
+0.02
(+2.65%)
USD |
NASDAQ |
Apr 25, 16:00
Forte Biosciences Shareholders Equity (Quarterly): 35.31M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 35.31M |
| September 30, 2023 | 40.41M |
| June 30, 2023 | 24.88M |
| March 31, 2023 | 32.95M |
| December 31, 2022 | 38.82M |
| September 30, 2022 | 42.84M |
| June 30, 2022 | 38.21M |
| March 31, 2022 | 40.05M |
| Date | Value |
|---|---|
| December 31, 2021 | 41.55M |
| September 30, 2021 | 43.65M |
| June 30, 2021 | 49.91M |
| March 31, 2021 | 54.70M |
| December 31, 2020 | 58.98M |
| September 30, 2020 | 20.32M |
| June 30, 2020 | 24.88M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
20.32M
Minimum
Sep 2020
58.98M
Maximum
Dec 2020
39.16M
Average
40.05M
Median
Mar 2022
Shareholders Equity (Quarterly) Benchmarks
| CEL-SCI Corp | 12.65M |
| AIM ImmunoTech Inc | 10.23M |
| IGC Pharma Inc | 9.053M |
| NovaBay Pharmaceuticals Inc | 3.314M |
| Protalix BioTherapeutics Inc | 33.57M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 38.98M |
| Total Liabilities (Quarterly) | 3.666M |